Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 4/2016

01-04-2016 | Antiphospholipid Syndrome (S Zuily, Section Editor)

Emerging Therapies in Antiphospholipid Syndrome

Authors: Danieli Andrade, Maria Tektonidou

Published in: Current Rheumatology Reports | Issue 4/2016

Login to get access

Abstract

Antiphospholipid syndrome (APS) is a hypercoagulable state characterized by arterial and venous thromboses and pregnancy morbidity in the presence of antiphospholipid antibodies. Although warfarin remains the main therapeutic choice in APS, there is still concern about its efficacy, safety, and patient compliance. Patients with refractory APS to conventional therapy as well as patients with non-classical manifestations of APS may have alternative treatment approaches. APS pathogenesis has been further elucidated over the past years identifying new molecules as potential new treatment targets. This review summarizes available data from in vitro and animal models and clinical studies on the role of new potential treatment approaches including new oral anticoagulants and immunoregulatory agents: direct thrombin or factor Xa inhibitors, hydroxychloroquine, statins, B cell inhibition, complement inhibition, peptide therapy, nuclear factor κB and p38 mitogen-activated kinase inhibitors, defibrotide, abciximab, mTOR inhibitor, and other potential targets. Large multicenter prospective studies of well-characterized APS patients are needed to assess the efficacy and safety profile of these potential treatment alternatives.
Literature
1.
2.••
Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13:685–9. This is a systematic review of potential future treatment strategies for antiphospholipid positive patients that includes recommendations for clinicians based on literature review and experts opinion.CrossRefPubMed
3.
Chighizola CB, Raschi E, Borghi MO, et al. Update on the pathogenesis and treatment of the antiphospholipid syndrome. Curr Opin Rheumatol. 2015;27:476–82.CrossRefPubMed
4.
Hoffman R, Brenner B. The promise of novel direct oral anticoagulants. Best Pract Res Clin Haematol. 2012;25:351–60.CrossRefPubMed
5.
Arachchillage DJ, Cohen H. Use of new oral anticoagulants in antiphospholipid syndrome. Curr Rheumatol Rep. 2013;15:331.CrossRefPubMed
6.
Schaefer JK, McBane RD, Black DF, et al. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost. 2014;112:947–50.CrossRefPubMed
7.•
Noel N, Dutasta F, Costedoat-Chalumeau N, et al. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev. 2015;14:680–5. This is the first retrospective observational cases series which examined the safety and efficacy of new oral anticoagulants in APS.CrossRefPubMed
8.
Win K, Rodgers GM. New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol. 2014;89:1017.CrossRefPubMed
9.
Signorelli F, Nogueira F, Domingues V, Mariz HA, Levy RA. Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clin Rheumatol. 2015 Jul 30.
10.•
Cohen H, Doré CJ, Clawson S, RAPS Trial Protocol Collaborators, et al. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. Lupus. 2015;24:1087–94. This is the first randomized trial comparing rivaroxaban with warfarin in patients with thrombotic APS. The final results of the trial are pending.CrossRefPubMedPubMedCentral
11.
Belizna C. Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. Autoimmun Rev. 2015;14:358–62.CrossRefPubMed
12.
Edwards MH, Pierangeli S, Liu X, et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation. 1997;96:4380–4.CrossRefPubMed
13.
Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood. 2008;112:1687–95.CrossRefPubMedPubMedCentral
14.
Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood. 2010;115:2292–9.CrossRefPubMedPubMedCentral
15.
Kuznik A, Bencina M, Svajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186:4794–804.CrossRefPubMed
16.
Wu XX, Guller S, Rand JH. Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression. Am J Obstet Gynecol. 2011;205:576–14.PubMedPubMedCentral
17.
Marchetti T, Ruffatti A, Wuillemin C, et al. Hydroxychloroquine restores trophoblast fusion affected by antiphospholipid antibodies. J Thromb Haemost. 2014;12:910–20.CrossRefPubMed
18.
Johnson R, Charnley J. Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty. Clin Orthop Relat Res. 1979;144:174–7.PubMed
19.
Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis. 2009;68:238–41.CrossRefPubMedPubMedCentral
20.
Tektonidou MG, Laskari K, Panagiotakos DB, et al. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 2009;61:29–36.CrossRefPubMed
21.
Broder A, Putterman C. Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. J Rheumatol. 2013;40:30–3.CrossRefPubMedPubMedCentral
22.
Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford). 2002;41:924–9.CrossRef
23.
Erkan D, Lockshin MD, APS ACTION members. APS ACTION—AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking. Lupus. 2012;21:695–8.CrossRefPubMed
24.•
Schmidt-Tanguy A, Voswinkel J, Henrion D, et al. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost. 2013;11:1927–9. The first retrospective observational study showing the antithrombotic role of hydroxychloroquine as additional treatment to anticoagulants in patients with primary APS.PubMed
25.
26.
Mekinian A, Lazzaroni MG, Kuzenko A, SNFMI and the European Forum on Antiphospholipid Antibodies, et al. The efficacy of Hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study. Autoimmun Rev. 2015;14:498–502.CrossRefPubMed
27.
Sciascia S, Branch DW, Levy RA et al. The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. Thromb Haemost. 2015;115.
28.
Ferrara DE, Liu X, Espinola RG, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum. 2003;48:3272–9.CrossRefPubMed
29.
Meroni PL, Raschi E, Testoni C, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum. 2001;44:2870–8.CrossRefPubMed
30.
Cortellaro M, Cofrancesco E, Arbustini E, et al. Systemic cause of unstable atherosclerotic plaques. Atorvastatin and Thrombogenicity of Carotid Atherosclerotic Plaque (ATROCAP) study group. Lancet. 2000;355:1362–3.CrossRefPubMed
31.
Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360:1851–61.CrossRefPubMedPubMedCentral
32.
Ferrara DE, Swerlick R, Casper K, et al. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost. 2004;2:1558–63.CrossRefPubMed
33.
Girardi G. Pravastatin prevents miscarriages in antiphospholipid antibody-treated mice. J Reprod Immunol. 2009;82:126–31.CrossRefPubMed
34.
López-Pedrera C, Ruiz-Limón P, Aguirre MA, et al. Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis. 2010;70:675–82.CrossRefPubMed
35.
Erkan D, Willis R, Murthy VL, et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis. 2014;73:1176–80.CrossRefPubMedPubMedCentral
36.
Pons I, Espinosa G, Cervera R. Efficacy and safety of rituximab in the treatment of primary antiphospholipid syndrome: analysis of 24 cases from the bibliography review. Med Clin. 2015;144:97–104.CrossRef
37.
Ramos-Casals M, Brito-Zerón P, Muñoz S, BIOGEAS study group, et al. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine. 2008;87:345–64.CrossRefPubMed
38.
Ioannou Y, Lambrianides A, Cambridge G, et al. B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres. Ann Rheum Dis. 2008;67:425–6.CrossRefPubMed
39.
Erre GL, Pardini S, Faedda R, et al. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus. 2008;17:50–5.CrossRefPubMed
40.•
Erkan D, Vega J, Ramón G, et al. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 2013;65:464–71. A prospective pilot study showing a beneficial effect of rituximab in microthrombotic/microangiopathic non-criteria manifestations of APS.CrossRefPubMed
41.
Berman H, Rodríguez-Pintó I, Cervera R, Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies), et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013;12:1085–90.CrossRefPubMed
42.
Rodríguez-Pintó I, Cervera R, Espinosa G. Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome. Ther Adv Musculoskelet Dis. 2015;7:26–30.CrossRefPubMedPubMedCentral
43.
Salmon JE, Girardi G, Lockshin MD. The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients. Nat Clin Pract Rheumatol. 2007;3:140–7.CrossRefPubMed
44.
Ikeda K, Nagasawa K, Horiuchi T, et al. C5a induces tissue factor activity on endothelial cells. Thromb Haemost. 1997;77:394–8.PubMed
45.
Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003;112:1644–54.CrossRefPubMedPubMedCentral
46.
Girardi G, Yarilin D, Thurman JM, et al. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med. 2006;203(9):2165–75.CrossRefPubMedPubMedCentral
47.
Holers VM, Salmon JE, Pickering MC, de Jorge EG, Martinez-Barricarte R, et al. Spontaneous hemolytic uremic syndrome triggered by complement surface recognition domains. J Exp Med. 2007;204:1249–56.CrossRef
48.
Salmon JE, Heuser C, Triebwasser M et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. Plos Med. 2011;doi: 10.1371.
49.
Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233–43.CrossRefPubMed
50.
Nishimura J, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014;370:632–9.CrossRefPubMed
51.
Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–81.CrossRefPubMed
52.
Tektonidou MG, Sotsiou F, Moutsopoulos HM. Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS. J Rheumatol. 2008;35(10):1983–8.PubMed
53.
Canaud G, Kamar N, Anglicheau D, et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant. 2013;13:2179–85.CrossRefPubMed
54.••
Shapira I, Andrade D, Allen SL, Salmon JE. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum. 2012;64:2719–23. The first report of the efficacy of eculizumab, an inhibitor of complement activation, in the treatment of CAPS demonstrating the importance of terminal complement components in the pathogenesis of CAPS and the therapeutic benefit of complement inactivation.CrossRefPubMed
55.
Ostertag MV, Liu X, Henderson SS, Pierangeli SS. A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice. Lupus. 2006;15:358–65.CrossRefPubMed
56.
Pedrera-Lopez CH, Aguirre MA, Limon-Ruiz P, et al. Immunotherapy in antiphospholipid syndrome. Int Immunopharmacol. 2015;27:200–8.CrossRef
57.
Ioannou Y, Romay-Penabad Z, Pericleus C, et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I; proof of concept. J ThrombHaemost. 2009;7:833–42.CrossRef
58.
de la Torre YM, Pregnolato F, D’Amelio F, et al. Antiphospholipid-induced murine fetal loss: novel protective effects of a peptide targeting the beta-2 glycoprotein I phospholipid binding site. Implication for human fetal loss. J Autoimmun. 2012;38:209–15.CrossRef
59.
Di Simone N, D’Ippolito S, Marana R, et al. Antiphospholipid antibodies affect human endometrial angiogenesis protective effect of synthetic peptide (TIFI) mimicking the antiphospholipid binding site of β(2) glycoprotein I. Am J Reprod immunol. 2013;70:299–08.CrossRefPubMed
60.•
Agostinis C, Durigutto P, Sblattero D, Borghi M, et al. A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood. 2014;123:3478–87. This study showed that the CH2-deleted antibody may represent an innovative approach to treat patients with APS refractory to standard therapy.CrossRefPubMed
61.
Benhamou Y, Bellien J, Armengol G, Brakenhielm E, et al. Role of toll-like receptors 2 and 4 in mediating endothelial dysfunction and arterial remodeling in primary arterial antiphospholipid syndrome. Arthritis Rheumatol. 2014;66:3210–20.CrossRefPubMed
62.
Comarmond C, Cacoub P. Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies. Autoimmun Rev. 2013;12:752–7.CrossRefPubMed
63.
Kubota T, Fukuya Y, Hashimoto R, et al. Possible involvement of chemokine induced platelet activation in thrombophilic diathesis of antiphospholipid syndrome. Ann N Y Acad Sci. 2009;1173:137–45.CrossRefPubMed
64.
Nishimura M, Nii T, Trimova G, et al. The NF-κβ specific inhibitor DHMEQ prevents thrombus formation in a mouse model of antiphospholipid syndrome. J Nephropathology. 2013;2:114–21.CrossRefPubMedPubMedCentral
65.
Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009;60:1231–41.CrossRef
66.
Marti V, Seixo F, Santaló M, Serra A. Antiphospholipid syndrome and acute myocardial infarction: treatment with thrombectomy and abciximab. Rev Port Cardiol. 2014;33:7–8.
67.
Chambers Jr JD, Haire HD, Deligonul U. Multiple early percutaneous transluminal coronary angioplasty failures related to lupus anticoagulant. Am Heart J. 1996;132:189–90.CrossRefPubMed
68.
Pierangeli SS, Vega-Ostertag M, Harris NE. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. Thromb Res. 2004;114:467–76.CrossRefPubMed
69.
Falanga A, Vignoli A, Marchetti M, Barbui T. Defibrotide reduces procoagulant activity and increase fibrinolytic properties of endothelial cells. Leukemia. 2003;17:1636–42.CrossRefPubMed
70.
Ferrari PA, Cornelli U, Dian F, et al. Defibrotide in the prevention of deep venous thrombosis in general surgery. Preliminary results of a multicenter study. Minerva Med. 1988;79:557–61.
71.
Burcoglu-O’Ral A, Erkan D, Asherson R. Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J Rheumatol. 2002;29:2006–11.PubMed
72.
Martin KA, Rzucidlo EM, Merenick BL, Fingar DC, Brown DJ, Wagner RJ, et al. The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation. Am J Physiol Cell Physiol. 2004;286:C507–17.CrossRefPubMed
73.
Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 1999;99:2164–70.CrossRefPubMed
74.
Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one year angiographic and intravascular ultrasound follow-up. Circulation. 2001;104:2007–11.CrossRefPubMed
75.
Hughson MD, McCarty GA, Brumback RA. Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome. J Am Soc Nephrol. 2002;13:42–52.
76.
Nochy D, Daugas E, Droz D, et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol. 1999;10:507–18.PubMed
77.••
Canaud G, Bienaimé F, Tabarin F, et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med. 2014;371:303–12. This is a recent study that suggests the role of the mTORC pathway in renal APS vascular lesion pathogenesis and the importance of its inhibition.CrossRefPubMed
78.
Zuily S, Regnault V, Wahl D. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med. 2014;16(371):1553–4.
Metadata
Title
Emerging Therapies in Antiphospholipid Syndrome
Authors
Danieli Andrade
Maria Tektonidou
Publication date
01-04-2016
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 4/2016
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-016-0566-z

Other articles of this Issue 4/2016

Current Rheumatology Reports 4/2016 Go to the issue

Surgery and Perioperative Care (CR MacKenzie and SM Goodman, Section Editors)

Racial/Ethnic Disparity in Rates and Outcomes of Total Joint Arthroplasty

Chronic Pain (R Staud, Section Editor)

Juvenile Fibromyalgia: Different from the Adult Chronic Pain Syndrome?

Systemic Lupus Erythematosus (G Tsokos, Guest Section Editor)

Mortality in Systemic Lupus Erythematosus: an Updated Review

Pediatric Rheumatology (S Ozen, Section Editor)

Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome: a Review of the Pathogenesis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits